CORD has partnered with Liaison International to create an Emergency Medicine Application in their ResidencyCAS platform as an alternative to the existing Association of American Medical Colleges (AAMC) Electronic Residency Application Service (ERAS) application. ResidencyCAS is the platform that OB/GYN transitioned to and has been using for this 2024-2025 application season. The CORD Application Process Improvement Committee (APIC) engaged in almost a year of research, evaluating several alternate platforms, and with the assistance of the CORD Board of Directors, have determined that ResidencyCAS is the platform best suited to meeting the needs of our specialty and our future workforce.
Please see here for the collaboration announcement.
For further context and background information leading to this decision, please watch the recording of our CORD Special Session - Evolving the Application Process: APIC’s Platform Exploration from October 17, 2024.
Please see here for some FAQs about the ResidencyCAS partnership.
As we collaborate with ResidencyCAS to create our application customized to EM, we have the opportunity to tailor it to highlight the information most important to you and to the processes that best support your workflow. In order to do that, we need to hear from you!
Upcoming Focus Groups:
Program Directors Focus Group: October 31, 2024 at 2pm ET.
EMARC Focus Group: November 5, 2024 at 3pm ET.
Dean/Student Affairs Representatives Focus Group: November 13, 2024 at 3pm ET.
Program Leadership Focus Group: November 18, 2024 at 10:30am ET.
Open Focus Group: December 4, 2024 at 7:00pm ET.
Open Focus Group: December 6, 2024 at 12pm ET. Watch the Recording
More dates coming soon!
The Alternate Application Working Group, lead by APIC, but with representation from across the stakeholder spectrum, will collate your suggestions and continue to represent you and your perspectives in the creation of this EM application.
It is also incredibly important that we continue to monitor OB/GYN’s experience with ResidencyCAS this year as we weigh the decision whether to make the switch for EM for the next cycle. Should we make the transition to this new platform, we want the change to be as smooth as possible, learning from the experiences of our OB/GYN colleagues. We encourage you to speak with your colleagues in OB/GYN (program directors, advisors, program coordinators, students) as well as in your Dean’s offices to gather their thoughts and perspectives. While we develop our platform and learn from OB/GYN’s ResidencyCAS experience, we will also continue to monitor the offerings and performance of ERAS and Thalamus in this application cycle.
Please share any feedback you may have about ResidencyCAS and/or ERAS/Thalamus (with as much specifics as possible) through this form.
We hope you will stay curious, stay engaged, and we look forward to hearing from you!